{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T11:44:41Z","timestamp":1785671081247,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychiatr"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>In this report, we present a case of a 16,9-year-old patient with multiple substance use disorder (cannabis, MDMA, cocaine, ecstacy), severe depression, social phobia and narcissistic personality disorder.<\/jats:p><jats:p>We administered Cannabidiol (CBD) capsules in different dosages (starting dosage 100 mg up to 600 mg over 8 weeks) after unsuccessful treatment with antidepressants.<\/jats:p><jats:p>CBD was a safe and well tolerated medication for this patient. Upon treatment with CBD and cessation of the antidepressant medication, the patient improved regarding depressive as well as anxiety symptoms including simple phobias and symptoms of paranoia and dissociation. Furthermore, the patient quit abusing illegal drugs including THC without showing withdrawal symptoms. This is the first report of CBD medication in a patient with multiple substance use disorder with a positive outcome.<\/jats:p><jats:p>Until today it is not clear if CBD holds promise as a therapeutic option in substance use disorder as RCTs are lacking, but in this single case the substance seems to work in various domains.<\/jats:p>","DOI":"10.1007\/s40211-020-00334-0","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T17:02:42Z","timestamp":1581526962000},"page":"31-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression","Cannabidiol-Therapie eines Jugendlichen mit multiplem Substanzabusus, Sozialphobie und Depression"],"prefix":"10.1007","volume":"35","author":[{"given":"Clarissa","family":"Laczkovics","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oswald D.","family":"Kothgassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Felnhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia M.","family":"Klier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"issue":"3","key":"334_CR1","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"35","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya\u00a0S, Morrison\u00a0PD, Fusar-Poli\u00a0P, Martin-Santos\u00a0R, Borgwardt\u00a0S, Winton-Brown\u00a0T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764\u201374.","journal-title":"Neuropsychopharmacology"},{"key":"334_CR2","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke\u00a0FM, Piomelli\u00a0D, Pahlisch\u00a0F, Muhl\u00a0D, Gerth\u00a0CW, Hoyer\u00a0C, et\u00a0al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"334_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire\u00a0P, Robson\u00a0P, Cubala\u00a0WJ, Vasile\u00a0D, Morrison\u00a0PD, Barron\u00a0R, et\u00a0al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175(3):225\u201331.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"334_CR4","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","volume":"235","author":"DL Boggs","year":"2018","unstructured":"Boggs\u00a0DL, Surti\u00a0T, Gupta\u00a0A, Gupta\u00a0S, Niciu\u00a0M, Pittman\u00a0B, et\u00a0al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a\u00a0randomized placebo controlled trial. Psychopharmacology. 2018;235(7):1923\u201332.","journal-title":"Psychopharmacology"},{"issue":"11","key":"334_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","volume":"75","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya\u00a0S, Wilson\u00a0R, Appiah-Kusi\u00a0E, O\u2019Neill\u00a0A, Brammer\u00a0M, Perez\u00a0J, et al. Effect of cannabidiol on medial temporal, midbrain, and Striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. Jama Psychiatry. 2018;75(11):1107\u201317.","journal-title":"Jama Psychiatry"},{"issue":"6","key":"334_CR6","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi\u00a0MM, Queiroz\u00a0RH, Chagas\u00a0MH, de Oliveira\u00a0DC, De Martinis\u00a0BS, Kapczinski\u00a0F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36(6):1219\u201326.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"334_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"JA Crippa","year":"2011","unstructured":"Crippa\u00a0JA, Derenusson\u00a0GN, Ferrari\u00a0TB, Wichert-Ana\u00a0L, Duran\u00a0FL, Martin-Santos\u00a0R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a\u00a0preliminary report. J\u00a0Psychopharmacol. 2011;25(1):121\u201330.","journal-title":"J Psychopharmacol"},{"key":"334_CR8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.18101191","author":"YL Hurd","year":"2019","unstructured":"Hurd\u00a0YL, Spriggs\u00a0S, Alishayev\u00a0J, Winkel\u00a0G, Gurgov\u00a0K, Kudrich\u00a0C, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019; https:\/\/doi.org\/10.1176\/appi.ajp.2019.18101191.","journal-title":"Am J Psychiatry"},{"key":"334_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7812\/TPP\/18-041","volume":"23","author":"S Shannon","year":"2019","unstructured":"Shannon\u00a0S, Lewis\u00a0N, Lee\u00a0H, Hughes\u00a0S. Cannabidiol in anxiety and sleep: a large case series. Perm\u00a0J. 2019;23:18\u201341.","journal-title":"Perm J"},{"issue":"1","key":"334_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/JCP.0000000000001152","volume":"40","author":"CM Klier","year":"2019","unstructured":"Klier\u00a0CM, de Gier\u00a0C, Felnhofer\u00a0A, Laczkovics\u00a0C, Amminger\u00a0P. High dose cannabidiol treatment of a\u00a0Crohn\u2019s disease patient with anxiety disorder. J\u00a0Clin Psychopharmacol. 2019;40(1):90\u20131.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"334_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","volume":"71","author":"DJ Allsop","year":"2014","unstructured":"Allsop\u00a0DJ, Copeland\u00a0J, Lintzeris\u00a0N, Dunlop\u00a0AJ, Montebello\u00a0M, Sadler\u00a0C, et\u00a0al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a\u00a0randomized clinical trial. JAMA Psychiatry. 2014;71(3):281\u201391.","journal-title":"JAMA Psychiatry"},{"key":"334_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.drugalcdep.2016.02.020","volume":"161","author":"JM Trigo","year":"2016","unstructured":"Trigo\u00a0JM, Lagzdins\u00a0D, Rehm\u00a0J, Selby\u00a0P, Gamaleddin\u00a0I, Fischer\u00a0B, et al. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend. 2016;161:298\u2013306.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"334_CR13","doi-asserted-by":"publisher","first-page":"e0190768","DOI":"10.1371\/journal.pone.0190768","volume":"13","author":"JM Trigo","year":"2018","unstructured":"Trigo\u00a0JM, Soliman\u00a0A, Quilty\u00a0LC, Fischer\u00a0B, Rehm\u00a0J, Selby\u00a0P, et\u00a0al. Nabiximols combined with motivational enhancement\/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PLoS ONE. 2018;13(1):e190768.","journal-title":"PLoS ONE"},{"key":"334_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2019.08.002","author":"S Bonaccorso","year":"2019","unstructured":"Bonaccorso\u00a0S, Ricciardi\u00a0A, Zangani\u00a0C, Chiappini\u00a0S, Schifano\u00a0F. Cannabidiol (CBD) use in psychiatric disorders: a systematic. Neurotoxicology. 2019; https:\/\/doi.org\/10.1016\/j.neuro.2019.08.002.","journal-title":"Neurotoxicology"},{"key":"334_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30401-8","author":"N Black","year":"2019","unstructured":"Black\u00a0N, Stockings\u00a0E, Campbell\u00a0G, Tran\u00a0LT, Zagic\u00a0D, Hall\u00a0WD, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a\u00a0systematic review and meta-analysis. Lancet Psychiatry. 2019; https:\/\/doi.org\/10.1016\/S2215-0366(19)30401-8.","journal-title":"Lancet Psychiatry"},{"key":"334_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/1471-244X-13-210","volume":"13","author":"S Doering","year":"2013","unstructured":"Doering\u00a0S, Burgmer\u00a0M, Heuft\u00a0G, Menke\u00a0D, Baumer\u00a0B, Lubking\u00a0M, et\u00a0al. Reliability and validity of the German version of the Structured Interview of Personality Organization (STIPO). BMC Psychiatry. 2013;13:210.","journal-title":"BMC Psychiatry"},{"key":"334_CR17","volume-title":"BDI-II. Beck-Depressions-Inventar. Revision","author":"M Hautzinger","year":"2009","unstructured":"Hautzinger\u00a0M, Keller\u00a0F, K\u00fchner\u00a0C. BDI-II. Beck-Depressions-Inventar. Revision. Frankfurt: Pearson Assessment; 2009."},{"key":"334_CR18","volume-title":"Phobiefragebogen f\u00fcr Kinder und Jugendliche: PHOKI","author":"M D\u00f6pfner","year":"2006","unstructured":"D\u00f6pfner\u00a0M. Phobiefragebogen f\u00fcr Kinder und Jugendliche: PHOKI. G\u00f6ttingen: Hogrefe; 2006."},{"issue":"01\/02","key":"334_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1055\/s-0038-1626434","volume":"25","author":"K Maurer","year":"2006","unstructured":"Maurer\u00a0K, H\u00f6rrmann\u00a0F, Trendler\u00a0G, Schmidt\u00a0M, H\u00e4fner\u00a0H, Maier\u00a0W et\u00a0al. Fr\u00fcherkennung des Psychoserisikos mit dem Early Recognition Inventory (ERIraos). Nervenheilkunde. 2006;25(01\/02):11\u20136.","journal-title":"Nervenheilkunde"},{"key":"334_CR20","volume-title":"Wechsler Intelligenztest f\u00fcr Erwachsene (Wechsler Intelligence Scale for adults)","author":"M Von Aster","year":"2006","unstructured":"Von Aster\u00a0M, Neubauer\u00a0A, Horn\u00a0R. Wechsler Intelligenztest f\u00fcr Erwachsene (Wechsler Intelligence Scale for adults). G\u00f6ttingen: Hogrefe; 2006."},{"issue":"6","key":"334_CR21","first-page":"31","volume":"14","author":"S Shannon","year":"2015","unstructured":"Shannon\u00a0S, Opila-Lehman\u00a0J. Cannabidiol oil for decreasing addictive use of marijuana: a case report. Integr Med. 2015;14(6):31\u20135.","journal-title":"Integr Med"},{"key":"334_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/fphar.2016.00422","volume":"7","author":"C Rohleder","year":"2016","unstructured":"Rohleder\u00a0C, Muller\u00a0JK, Lange\u00a0B, Leweke\u00a0FM. Cannabidiol as a\u00a0potential new type of an antipsychotic. A critical review of the evidence. Front Pharmacol. 2016;7:422.","journal-title":"Front Pharmacol"}],"container-title":["neuropsychiatrie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40211-020-00334-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40211-020-00334-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40211-020-00334-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T13:22:47Z","timestamp":1615555367000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40211-020-00334-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["334"],"URL":"https:\/\/doi.org\/10.1007\/s40211-020-00334-0","relation":{},"ISSN":["0948-6259","2194-1327"],"issn-type":[{"value":"0948-6259","type":"print"},{"value":"2194-1327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"5 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.\u00a0Laczkovics, O.D.\u00a0Kothgassner, A.\u00a0Felnhofer, and C.M.\u00a0Klier declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}